Nucleo Analysis: $4M Raised

Automatic detection of fat and muscle mass in CT scans; Precise measurement of tumor lesions; Automated classification of lesions according to RECIST criteria; Streamlining clinical workflows in oncology; Supporting healthcare providers with rapid analysis

Nucleo specializes in automating CT scan analysis for oncology care, focusing on three main product offerings: body composition analysis, tumor lesion sizing, and target vs non-target lesion classification.

1. Body Composition Analysis: This feature allows for the automatic detection and quantification of fat and muscle mass in CT scans, which is crucial for assessing patient health and treatment responses.

2. Tumor Lesion Sizing: Nucleo provides precise and consistent measurement of tumor lesions, enhancing the accuracy of cancer assessments and treatment planning.

3. Target vs Non-Target Lesion Classification: Utilizing RECIST criteria, this automated classification helps in distinguishing between lesions that are being treated and those that are not, facilitating better monitoring of treatment efficacy.

The key benefits of Nucleo's offerings include rapid analysis capabilities that achieve high agreement rates with expert radiologists, significantly faster than manual segmentation processes. This technology is particularly beneficial for oncology departments in hospitals and healthcare providers seeking automation in CT scan analysis.

Backed by Y Combinator; Collaborates with top hospitals in the US and worldwide; Achieves high agreement rates with expert radiologists